secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2022-02-02T23:59:59+00:00
Accession:  0001493152-22-002955
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic issues $0.5M convertible note to Golden Mountain Partners as part of $1.5M funding
--------------------------------------------------------------------------------

- Issued $0.5M unsecured convertible note to Golden Mountain Partners, part of up to $1.5M total in three monthly installments.
- Note carries 2% annual interest, matures one year from date, convertible into common stock at closing bid price.
- Proceeds to support payroll and clinical development of OT-101.
- Note contains standard events of default; prepayment allowed with accrued interest.
- Conversion shares unregistered, issued under Rule 506.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315222002955/0001493152-22-002955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315222002955/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-002955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer